Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human

Xenobiotica

Volumn 43, Issue 7, 2013, Pages 607-616

  Bueters, Tjerk ^a   Juric, Sanja ^a   Sohlenius Sternbeck, Anna Karin ^a   Hu, Yin ^a   Bylund, Johan ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Interspecies correlation; Intestinal metabolism; Oral bioavailability; Pharmacokinetics

Indexed keywords

CYTOCHROME P450; NISOLDIPINE; NIZATIDINE; OMEPRAZOLE; PHENYTOIN; PRAVASTATIN; PRAZOSIN; PREDNISOLONE; PROPRANOLOL; PROPYLTHIOURACIL; RANITIDINE; REBOXETINE; RECAINAM; REMOXIPRIDE; RIFABUTIN; RISPERIDONE; RITONAVIR; SAQUINAVIR; SILDENAFIL; SITAGLIPTIN; SULPIRIDE; THEOPHYLLINE; TOLBUTAMIDE; TOLTERODINE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; ZOLPIDEM; ZOPICLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MARKETING; DRUG METABOLISM; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINAL LOSS; KIDNEY CLEARANCE; LIVER CLEARANCE; MALE; MICROSOME; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; RAT;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; METABOLIC CLEARANCE RATE; MICROSOMES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

RATTUS;

EID: 84878842012     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.752117     Document Type: Article

References (86)

1. Ahr HJ, Krause HP, Siefert HM, et al. (1988). Pharmacokinetics of nisoldipine. I Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine. Arzneimittel-Forschung 38:1093-8.
2. Bäärnhielm C, Dahlbäck H, Ska°nberg I. (1986). In vivo pharmacoki-netics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol Toxicol 59:113-22. (Pubitemid 16043503)
3. Beconi MG, Reed JR, Teffera Y, et al. (2007). Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Disp 35:525-32. (Pubitemid 46513254)
4. Briem S, Martinsson S, Bueters T, Skoglund E. (2007). Combined approach for high-throughput preparation of plasma samples from exposure studies. Rapid Commun Mass Spectrom 21:1965-72. (Pubitemid 46999246)
5. Bueters T, Dahlström J, Kvalva°gnaes K, et al. (2011). High-throughput analysis of standardized pharmacokinetic studies in the rat using sample pooling and UPLC-MS/MS. J Pharm Biomed Anal 55:1120-6.
6. Cao X, Gibbs ST, Fang L, et al. (2006). Why it is challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-86. (Pubitemid 44200529)
7. Carlos MA, Du Souich P, Carlos R, et al. (2002). Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. J Pharm Sci 91:1627-38. (Pubitemid 34680225)
8. Chen M, Xu D, Hu X-L, Wang H. (2008). Effects of liver fibrosis on verapamil pharmacokinetics in rats. Clin Exp Pharmacol Physiol 35:287-94. (Pubitemid 351257881)
9. Chiou WL, Barve A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats. Pharm Res 15:1792-5. (Pubitemid 28524594)
10. Chiou WL, Buehler PW. (2002). Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 19:868-74. (Pubitemid 34686748)
11. Cho YA, Choi JS, Burm JP. (2011). Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of p-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol Rep 63:1066-73.
12. Choi J-S, Piao Y-L, Han H-K. (2006). Pharmacokinetic interaction between fluvastatin and diltiazem in rats. Biopharm Drug Disp 27:437-41.
13. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. (2010). Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the Advanced Dissolution, Absorption, Metabolism (ADAM) model. Curr Drug Metab 11:716-29.
14. De Buck SS, Sinha VK, Fenu LA, et al. (2007). The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Disp 35:649-59. (Pubitemid 46513269)
15. Dostert P, Benedetti MS, Pogessi I. (1997). Review of the pharmaco-kinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 7:S23-35. (Pubitemid 27240333)
16. Durand A, Thenot JP, Bianchetti G, Morselli PL. (1992). Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev 24:239-66.
17. Fagerholm U. (2007). Prediction of human pharmacokinetics- gastrointestinal absorption. J Pharm Pharmacol 59:905-16.
18. Fan J, Chen S, Chow EC, Pang KS. (2010). PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 11:743-61.
19. Fisher MB, Labissiere G. (2007). The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Curr Drug Metab 8:694-9. (Pubitemid 47578117)
20. Foster RT, Jamali F. (1988). Stereoselective pharmacokinetics of ketoprofen in the rat: influence of route of administration. Drug Metab Disp 16:623-6.
21. Gaillot J, Heusse D, Hougton GW, et al. (1983). Pharmacokinetics and metabolism of zopiclone. Pharmacology 27:76-91. (Pubitemid 14181629)
22. Galetin A, Gertz M, Houston JB. (2008). Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert opin Drug Metab Toxicol 4:909-22.
23. Galetin A, Houston JB. (2006). Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220-9. (Pubitemid 44268329)
24. Garcia-Carbonell MC, Granero L, Torres-Molina F, et al. (1994). Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab Disp 21:215-7. (Pubitemid 23120092)
25. Gertz M, Harrison A, Houston JB, Galetin A. (2010). Prediction of human intestinal first-pass metabolism of 25 CYP3A4 substrates from in vitro clearance and permeability data. Drug Metab Dispos 38: 1147-58.
26. Gertz M, Houston JB, Galetin A. (2011). Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39:1633-44.
27. Grass GM, Sinko PJ. (2002). Physiologically-based pharmacokinetic simulation modeling. Adv Drug Deliv Rev 54:433-51.
28. Grundy JS, Eliot LA, Foster RT. (1997). Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Disp 18: 509-22. (Pubitemid 27338982)
29. Hallifax D, Foster JA, Houston JB. (2010). Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150-61.
30. Hatley O, Jones C, Galetin A, Rostami-Hodjegan A. (2011). Methodology optimization in intestinal microsome preparation: implications for scaling approaches? AAPS Annual Meeting and Exposition; Oct 23-27; Washington DC, USA.
31. Hellriegel ET, Bjornsson TD, Hauck WW. (1996). Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60:601-7. (Pubitemid 27025907)
32. Helton DR, Osborne DW, Pierson SK, et al. (2000). Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone. Drug Metab Disp 28:925-9. (Pubitemid 30612611)
33. Higuchi S, Shiobara Y. (1980). Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 10:447-54. (Pubitemid 10049541)
34. Hirunpanich V, Katagi J, Sethabouppha B, Sato H. (2006). Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporine in rats. Drug Metab Disp 34:305-10. (Pubitemid 43145032)
35. Howell SR, Hicks DR, Scatina JA, Sisenwine SF. (1994). Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Xenobiotica 24:315-27. (Pubitemid 24169005)
36. Hui Y-H, Huang NH, Ebbert L, et al. (2007). Pharmacokinetic comparisons of tail-bleeding with cannula-or retro-orbital bleeding techniques in rats using six marketed drugs. J Pharmacol Toxicol Meth 56:256-64. (Pubitemid 47375130)
37. Jamei M, Turner D, Yang J, et al. (2009). Population-based mechanistic predictions of oral drug absorption. AAPS J 11:225-37.
38. Jang SH, Lee MH, Lee MG. (1994). Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive wistar rats. J Pharm Sci 83:810-14. (Pubitemid 24233755)
39. Jeong EJ, Liu Y, Lin H, Hu M. (2005). Species-and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-94. (Pubitemid 40686632)
40. Kadono K, Akabane T, Tabata K, et al. (2010). Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230-7.
41. Kato M, Chiba K, Hisaka A, et al. (2003). The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokin 18:365-72.
42. Kim EJ, Han KS, Lee MG. (2000). Gastrointestinal first-pass effect of furosemide in rats. J Pharm Pharmacol 52:1337-43.
43. Kivistö KT, Grisk O, Hofmann U, et al. (2005). Disposition of oral and intravenous pravastatin in mrp2-deficient TR-rats. Drug Metab Disp 33:1593-6. (Pubitemid 41539954)
44. Komura H, Iwaki M. (2011). In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev 43:476-98.
45. Koudriakova T, Iatsimirskaia E, Tulebaev S, et al. (1996). In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats. J Pharmacol Exp Ther 279:1300-9. (Pubitemid 27166778)
46. Lee DY, Lee I, Lee MG. (2007). Pharmacokinetics of omeprazole after invenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int J Pharmaceut 330:37-44. (Pubitemid 46110950)
47. Lee SH, Lee MG, Kim ND. (1994). Pharmacokinetics and pharmaco-dynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokin Biopharmaceut 22:1-17. (Pubitemid 24153352)
48. Lennernäs H. (2007). Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 8:645-57. (Pubitemid 47578114)
49. Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-57. (Pubitemid 29269980)
50. Lindahl A, Sjöberg A, Bredberg U, et al. (2004). Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. Mol Pharmaceut 1:347-56.
51. Mandema JW, Gubbens-Stibbe JM, Danhof M. (1991). Stability and pharmacokinetics of flumazenil in the rat. Psychopharmacology 103:384-7.
52. Mandema JW, Tukker E, Danhof M. (1991). Pharmacokinetic-pharma-codynamic modeling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 102:663-8.
53. Mattiuz EL, Ponsler D, Barbuch RJ, et al. (2003). Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fisher 344 rat and Beagle dog. Drug Metab Disp 31:88-97. (Pubitemid 36735262)
54. McGinnity DF, Collington J, Austin RP, Riley RJ. (2007). Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab 8:463-79. (Pubitemid 47603410)
55. Mroszczak EJ, Lee FW, Combs D, et al. (1987). Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Disp 15:618-26. (Pubitemid 18004616)
56. Nishimuta H, Sato K, Yabuki M, Komura S. (2011). Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab Pharmacokinet 26: 592-601.
57. Nomeir AA, Morrison R, Prelusky D, et al. (2009). Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery. J Pharmaceut Sci 98: 4027-38.
58. Påhlman I, Kankaanranta S, Palmer L. (2001). Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Arzneimittel-Forschung 51:134-44.
59. Riley RJ, McGinnity DF, Austin RP. (2005). A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Disp 33:1304-11. (Pubitemid 41196973)
60. Sano H, Sato H, Furuta S, et al. (1991). Pharmacokinetics of nizatidine in dogs and rats. Xenobiotica 21:1257-64.
61. Scatina JA, Kimmel HB, Weinstein V, et al. (1990). Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug. Biopharm Drug Disp 11:445-61. (Pubitemid 20247813)
62. Segura J, Borja L, Bakke OM. (1976). Pharmacokinetics of sulpiride after oral and intravenous administration in the rat and the dog. Arch Int Pharmacodyn 223:88-95.
63. Siefert HM, Domdey-Bette A, Henninger K, et al. (1999). Pharmacokinetics of 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mamalian species. J Antimicrobiol Chemother 43:69-76. (Pubitemid 29231796)
64. Sietsema WK. (1989). The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27:179-211. (Pubitemid 19104397)
65. Shayeganpour A, Hamdy DA, Brocks DR. (2008). Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. Biopharm Drug Disp 29:159-66. (Pubitemid 351722160)
66. Shibata N, Gao W, Okamoto H, et al. (2002). Drug interactions between HIV protease inhibitors based on physiologically-based pharmacoki-netic model. J Pharmaceut Sci 91:680-9. (Pubitemid 34639631)
67. Shibata Y, Takahashi H, Ishii Y. (2000). A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Disp 28:1518-23.
68. Shin HS, Bae SK, Lee MG. (2006). Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects. Int J Pharmaceut 320:64-70. (Pubitemid 44128707)
69. Smith DA, Rasmussen HS, Stopher DA, Walker DK. (1992). Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22:709-19.
70. Sohlenius-Sternbeck A-K, Afzelius L, Prusis P, et al. (2010). Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637-49.
71. Sohlenius-Sternbeck A-K, Jones C, Ferguson D, et al. (2012). Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841-53.
72. Tachibana T, Kato M, Takakno J, Sugiyama Y. (2010). Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11:762-77.
73. Takahashi M, Washio T, Suzuki N, et al. (2009). The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and human. J Pharm Sci 98:4343-53.
74. Thomas VH, Bhattachar S, Hitchingham L, et al. (2006). The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2:591-608. (Pubitemid 46127071)
75. Thomsen AE, Christensen MS, Bagger MA, Steffansen B. (2004). Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. Eur J Pharm Sci 23:319-25. (Pubitemid 39573382)
76. Van de Kerkhof EG, De Graaf IAM, Groothuis GMM. (2007). In vitro methods to study intestinal drug metabolism. Curr Drug Metab 8:658-75. (Pubitemid 47578115)
77. Varma MVS, Obach RS, Rotter C, et al. (2010). Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem 53:1098-108.
78. Wang Y, Roy A, Sun L, Lau CE. (1999). A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Disp 27:855-9. (Pubitemid 29347583)
79. Ward KW, Nagilla R, Jolivette LJ. (2005). Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica 35:191-210. (Pubitemid 40769767)
80. Widman M, Nilsson LB, Bryske B, Lundström J. (1993). Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittel-Forschung 43:287-97. (Pubitemid 23093231)
81. Yamasaki H, Tabata S. (1993). Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats. Arzneimittel-Forschung 43:1317-21. (Pubitemid 24009937)
82. Yang J, Jamei M, Rowland Yeo K, et al. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-84. (Pubitemid 47578116)
83. Yang SH, Lee MG. (2007). Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability. Int J Pharmaceut 332:17-23. (Pubitemid 46227783)
84. Zhang J, Wang C, Liu Q, et al. (2010). Pharmacokinetic interaction between JBP485 and cephalexin in rats. Drug Metab Disp 38: 930-8.
85. Zhao YH, Abraham MH, Joelle L, et al. (2003). Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 38:233-43. (Pubitemid 36349666)
86. Zhao Y, Tao T, Wu J, et al. (2008). Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration. J Pharmacy Pharmacol 60:1149-54.